Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges
Adamantia Nikolaidi(Mitera Hospital), Christos Papadimitriou(National and Kapodistrian University of Athens), Elena Fountzilas(St. Luke's Hospital), Helen Gogas(National and Kapodistrian University of Athens), Florentia Fostira(National Centre of Scientific Research "Demokritos"), Amanda Psyrri(National and Kapodistrian University of Athens)
Cited by 35
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747